Bristol Myers Squibb’s Opdivo was recently granted FDA approval in combination with cisplatin and gemcitabine as a first-line treatment for metastatic urothelial carcinoma (mUC).
Mount Sinai investigators have developed a new approach for treating invasive bladder cancer without the need for surgical removal of the bladder, according to a study published in Nature Medicine in September.
IO Biotech, a clinical-stage biopharma company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has dosed the first patient in its phase 1 bladder cancer trial.